Skip to main content

Understand Your European Market Access Barriers

Identify reimbursement, payer and HTA barriers and define practical next steps.

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Med Tech-related technology assessments from NICE in October 2026

NICE develops HealthTech Guidance (HTG) to assess healthcare technologies, including diagnostics, medical devices and digital technologies such as artificial intelligence (AI), as well as interventional procedures. The programme evaluates the clinical and cost-effectiveness of HealthTech products and the safety and efficacy of interventional procedures.

NICE applies a lifecycle approach to HTG, reflecting the maturity and evidence base of each technology:

  • Early use: Innovative technologies with the potential to address unmet NHS needs but insufficient evidence to support routine adoption.
  • Routine use: Technologies with sufficient evidence to support widespread NHS adoption.
  • Existing use: Technologies already widely used in the NHS, assessed to inform commissioning and procurement decisions.

NICE recommendations generally fall into four categories: Can be used, Can be used during the evidence generation period, More research is needed, and Should not be used. Although recommendations are not legally binding, they are typically followed by NHS providers and commissioners.

In October 2026, NICE released three new early-use HTGs on the following topics:

AI-based software for interpreting electroencephalogram (EEG) in suspected epilepsy

NICE concluded that more research is needed on five assessed software technologies using AI-derived algorithms to help interpret EEGs in people with suspected epilepsy before they can be funded by the NHS.

Digital platforms supporting hip and knee replacement pathways

The assessment covers digital platforms supporting preparation before and rehabilitation after primary elective hip or knee replacement surgery.

NICE concluded that:

  • Four digital technologies can be used in the NHS during the evidence generation period as options to support preoperative preparation and postoperative rehabilitation.
  • More research is needed on 15 additional digital technologies before they can be considered for NHS funding.

XVIVO Perfusion System for lung transplantation

NICE concluded that the XVIVO Perfusion System, which uses ex-situ machine perfusion, can be used in the NHS during the evidence generation period to assess and recondition marginal lungs for transplantation in adults. The technology is intended to assess and recondition lungs that would otherwise not be accepted for donation or transplantation, potentially making them suitable for use in lung transplants. Its use is conditional on generating the evidence specified in NICE's evidence generation plan.

This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.